Home / Health / Common BP Meds May Damage Diabetic Kidneys
Common BP Meds May Damage Diabetic Kidneys
5 Jun
Summary
- Dihydropyridine calcium-channel blockers linked to 33% higher kidney damage risk.
- Study involved over 31,000 adults with type 2 diabetes.
- Findings suggest DCCBs might increase kidney pressure despite other protective drugs.
A recent analysis has indicated that a common class of blood pressure medications, dihydropyridine calcium-channel blockers (DCCBs), may be associated with an increased risk of kidney damage in individuals with type 2 diabetes. The study, which examined data from over 31,000 adults between 2016 and 2021, found a 33% higher risk of kidney damage for patients taking DCCBs alongside other standard kidney-protective therapies.
These therapies included renin-angiotensin system (RAS) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are crucial for managing diabetic kidney disease (DKD). Despite the presumed protective effects of these advanced treatments, the added use of DCCBs appeared to persist in increasing kidney disease progression. Researchers theorize that DCCBs might relax blood vessels leading into the kidneys without adequately relaxing those leaving, potentially elevating internal kidney pressure.
While the findings, presented on June 4, 2026, at the European Renal Association's congress in Glasgow, Scotland, raise significant questions about current treatment protocols, the study was observational. Therefore, it cannot definitively establish a cause-and-effect relationship. Medical professionals urge patients not to discontinue DCCBs without consulting their doctors, as further prospective studies and randomized controlled trials are necessary to validate these preliminary results and refine safe treatment strategies for DKD patients.
